BACKGROUND: This study evaluated differences in accuracy between the CONTOUR® NEXT EZ (EZ) blood glucose monitoring system (BGMS) and four other BGMSs [ACCU-CHEK® Aviva (ACAP), FreeStyle Freedom Lite® (FFL), ONE TOUCH® Ultra®2 (OTU2), and TRUEtrack® (TT)]. METHODS: Up to three capillary blood samples (N = 393) were collected from 146 subjects with and without diabetes. One sample per subject was tested with fresh (natural) blood; the other samples were glycolyzed to lower blood glucose to <70 mg/dl. Meter results were compared with results from plasma from the same sample tested on a Yellow Springs Instruments (YSI) 2300 STAT PlusTM glucose analyzer. Blood glucose monitoring system accuracy was compared using mean absolute relative difference (MARD; from laboratory reference method results) and other analyses. Separate analyses on fresh (natural) samples only were conducted to determine potential effects of glycolysis on MARD values of systems utilizing glucose-oxidase-based test strip chemistry. RESULTS: Across the tested glucose range, the EZ had the lowest MARD of 4.7%; the ACAP, FFL, OTU2, and TT had MARD values of 6.3%, 18.3%, 23.4%, and 26.2%, respectively. For samples with glucose concentrations <70 mg/dl, the EZ had the lowest MARD (0.65%), compared with the ACAP (2.5%), FFL (18.3%), OTU2 (22.4%), and TT (33.2%) systems. CONCLUSIONS: The EZ had the lowest MARD across the tested glucose ranges when compared with four other BGMSs when all samples were analyzed as well as when natural samples only were analyzed.
BACKGROUND: This study evaluated differences in accuracy between the CONTOUR® NEXT EZ (EZ) blood glucose monitoring system (BGMS) and four other BGMSs [ACCU-CHEK® Aviva (ACAP), FreeStyle Freedom Lite® (FFL), ONE TOUCH® Ultra®2 (OTU2), and TRUEtrack® (TT)]. METHODS: Up to three capillary blood samples (N = 393) were collected from 146 subjects with and without diabetes. One sample per subject was tested with fresh (natural) blood; the other samples were glycolyzed to lower blood glucose to <70 mg/dl. Meter results were compared with results from plasma from the same sample tested on a Yellow Springs Instruments (YSI) 2300 STAT PlusTM glucose analyzer. Blood glucose monitoring system accuracy was compared using mean absolute relative difference (MARD; from laboratory reference method results) and other analyses. Separate analyses on fresh (natural) samples only were conducted to determine potential effects of glycolysis on MARD values of systems utilizing glucose-oxidase-based test strip chemistry. RESULTS: Across the tested glucose range, the EZ had the lowest MARD of 4.7%; the ACAP, FFL, OTU2, and TT had MARD values of 6.3%, 18.3%, 23.4%, and 26.2%, respectively. For samples with glucose concentrations <70 mg/dl, the EZ had the lowest MARD (0.65%), compared with the ACAP (2.5%), FFL (18.3%), OTU2 (22.4%), and TT (33.2%) systems. CONCLUSIONS: The EZ had the lowest MARD across the tested glucose ranges when compared with four other BGMSs when all samples were analyzed as well as when natural samples only were analyzed.
Authors: Timothy S Bailey; Jane F Wallace; Joan Lee Parkes; Scott Pardo; Ji Yu; Holly C Schachner; David A Simmons; Amy Chu Journal: Diabetes Technol Ther Date: 2012-06-29 Impact factor: 6.118
Authors: Andreas Pfützner; Michael Mitri; Petra B Musholt; Daniela Sachsenheimer; Marcus Borchert; Andrew Yap; Thomas Forst Journal: Curr Med Res Opin Date: 2012-03-21 Impact factor: 2.580
Authors: Cornelius Tack; Harald Pohlmeier; Thomas Behnke; Volkmar Schmid; Marco Grenningloh; Thomas Forst; Andreas Pfützner Journal: Diabetes Technol Ther Date: 2011-12-16 Impact factor: 6.118
Authors: Catherine A Sheffield; Michael P Kane; Gary Bakst; Robert S Busch; Jill M Abelseth; Robert A Hamilton Journal: Diabetes Technol Ther Date: 2009-09 Impact factor: 6.118
Authors: Edward R Damiano; Firas H El-Khatib; Hui Zheng; David M Nathan; Steven J Russell Journal: Diabetes Care Date: 2012-12-28 Impact factor: 19.112